G21.19
Other drug induced secondary parkinsonism
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Inclusion Terms
- Other medication-induced parkinsonism
Medical Intelligence & Overview
Other drug-induced secondary parkinsonism (ICD-10 G21.19) refers to a condition where Parkinson-like symptoms develop as a side effect of certain medications. Unlike idiopathic Parkinson's disease, which has no clear external cause, this form is directly linked to drug exposure, particularly medications that affect dopamine levels in the brain. Recognizing this condition is essential for proper management and treatment, especially when symptoms emerge after starting new medication regimens.
Causes & Symptoms
Clinical Causes: Use of medications that block dopamine receptors, such as typical antipsychotics (e.g., haloperidol, chlorpromazine). Administration of drugs that alter dopamine pathways or levels, including certain anti-nausea medications like metoclopramide. Long-term use of medications with dopamine-depleting effects, potentially leading to Parkinson-like symptoms. Substances or drugs that interfere with the function of dopamine in the central nervous system.
Key Symptoms: Resting tremor, often starting in one hand Muscle rigidity or stiffness Bradykinesia or slowed movements Postural instability and balance difficulties Reduced facial expressions (masked face) Shuffling gait and difficulty initiating movements Dystonia or abnormal muscle tone
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a detailed medical history to identify recent medication use, along with clinical examination to observe characteristic Parkinson-like symptoms. Healthcare providers may review medication lists and consider discontinuing or switching the implicated drugs to see if symptoms improve. Additional diagnostic tests, such as neuroimaging or laboratory investigations, help rule out other causes of parkinsonism and confirm the diagnosis of drug-induced parkinsonism.
Treatment Protocols: The primary approach is to identify and modify the offending medication under medical supervision. In many cases, symptoms improve or resolve within weeks after stopping the causative drug. Supportive therapies, including physical and occupational therapy, can help manage motor symptoms. In some situations, medications used for Parkinson's disease, like levodopa, may be used cautiously, but their effectiveness varies. Regular monitoring is essential to evaluate symptom progression and medication adjustments.
Clinical Advice & FAQs
Billing Guidance
Is G21.19 a billable ICD-10 code?
Yes, G21.19 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G21.19?
Clinical documentation must specify the nature of Other drug induced secondary parkinsonism and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
